Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer
Antineoplastic Combined Chemotherapy Protocols
Receptor, Epidermal Growth Factor
p21 expression in colorectal cancer, especially in combination with p53 mutation, is a predictor of resistance to the combination chemotherapy with gefitinib. Activating EGFR mutations are rare in colorectal cancer and do not seem to confer sensitivity to gefitinib and chemotherapy.